Loïc Ysebaert

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 387 citations · Full text

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

Arnaud Jaccard, Nathalie Gachard, Benôıt Marin et al. · Blood · 2010 · 384 citations · Full text

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 357 citations · Full text

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Richard Delarue, Hervé Tilly, Nicolas Mounier et al. · The Lancet Oncology · 2013 · 298 citations

Hematological Malignancy, Dose-dense Rituximab-chop, Standard Rituximab-chop +6

The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

Catherine Thiéblemont, Josette Brière, Nicolas Mounier et al. · Journal of Clinical Oncology · 2011 · 274 citations